Unexpected Toxicity has Lessons for Making Bispecific Antibodies
By taking a detailed look at toxicities of a bispecific antibody that targets the transferrin receptor to cross the blood-brain-barrier, researchers at Genentech Inc. have gained new insights into both "important safety concerns and potential mitigation strategies" for the therapeutic development of such antibodies.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter